The global uncomplicated urinary tract infection treatment market garnered a market value of US$ 5.96 Billion in 2022 and is expected to accumulate a market value of US$ 17 Billion by registering a CAGR of 10% in the forecast period 2023 to 2033. Growth of the uncomplicated urinary tract infection treatment market can be attributed to high prevalence of UTIs, increasing antibiotic resistance, and the growing awareness of the importance of proper UTI management. The market for uncomplicated urinary tract infection treatment registered a CAGR of 5.7% in the historical period 2018 to 2022
Urinary tract infections are a common medical condition, particularly among women, and are usually caused by bacteria such as Escherichia coli (E. coli). Uncomplicated UTIs can be treated with antibiotics and other medications, such as pain relievers and urinary analgesics, which are designed to alleviate the symptoms of the infection.
The market for uncomplicated UTI treatments includes a range of prescription and over-the-counter medications, as well as natural remedies and alternative therapies. The market is expected to continue to grow in the coming years as new medications and therapies are developed and as the demand for effective and safe UTI treatments increases.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 6.55 Billion |
| Anticipated Forecast Value (2033) | US$ 17 Billion |
| Projected Growth Rate (2023 to 2033) | 10% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for uncomplicated urinary tract infection treatment reflected a value of 5.7% during the historical period, 2018 to 2022.
The market growth was driven by factors such as the high prevalence of UTIs, increasing antibiotic resistance, and the growing awareness of the importance of proper UTI management.
In terms of regional segmentation, North America accounted for the largest share of the Uncomplicated UTI Treatment Market in 2018, followed by Europe and Asia Pacific. The major players in the Uncomplicated UTI Treatment Market included Merck & Co., Inc., Pfizer Inc., Novartis AG, Bayer AG, and GlaxoSmithKline plc, among others. These companies were focused on product development, strategic partnerships, and mergers and acquisitions to expand their market presence and increase their market share.
Overall, the Uncomplicated UTI Treatment Market has been growing steadily over the past few years and is expected to continue to grow in the coming years, driven by factors such as the increasing demand for effective and safe UTI treatments and the development of new therapies and medications.
Thus, the market for uncomplicated urinary tract infection treatment is expected to register a CAGR of 10% in the forecast period 2023 to 2033.
High prevalence of UTIs along with increasing antibiotic resistance favoring market growth
UTIs are a common medical condition, particularly among women, and the high prevalence of UTIs drives the demand for UTI treatment products and services. Antibiotic resistance is a growing concern worldwide, and it is particularly relevant in the context of UTI treatment. As antibiotic resistance increases, there is a growing need for new and innovative treatments for UTIs.
There is a growing awareness among patients and healthcare professionals about the importance of proper UTI management. This increased awareness drives demand for effective and safe UTI treatments. The development of new technologies for UTI diagnosis, such as rapid diagnostic tests and point-of-care testing, are driving the growth of the UTI treatment market by enabling faster and more accurate diagnosis of UTIs.
As healthcare expenditure continues to rise worldwide, there is a growing demand for UTI treatment products and services, which are essential for the management of UTIs. The aging population is more susceptible to UTIs due to weakened immune systems and other factors, and this demographic trend is expected to drive the growth of the UTI treatment market.
Availability of treatments shaping landscape for uncomplicated urinary tract infection
Uncomplicated urinary tract infections (UTIs) are usually treated with antibiotics to eliminate the bacteria causing the infection. Some of the most commonly prescribed antibiotics for uncomplicated UTIs include:
Pain relievers and urinary analgesics may also be prescribed to alleviate the symptoms of the infection, such as pain and burning during urination. These include:
Principal Consultant
Lack of new drug development and limited awareness of UTI management derailing market growth
Antibiotic resistance is a growing concern worldwide, and it is particularly relevant in the context of UTI treatment. As antibiotic resistance increases, it becomes more difficult to effectively treat UTIs, leading to a growing need for new and innovative treatments. There is a lack of new drug development in the UTI treatment market, which can limit the availability of effective treatment options for patients.
Despite growing awareness of the importance of proper UTI management, there are still many patients and healthcare professionals who may not be fully aware of the best practices for UTI prevention and treatment. Some UTI treatment options, particularly alternative and natural remedies, may not be covered by insurance or reimbursed by healthcare providers, making them less accessible to patients.
In some regions, particularly in developing countries, there may be limited access to healthcare facilities and services, making it difficult for patients to receive proper diagnosis and treatment for UTIs.
Increasing awareness of UTI management propelling market growth in North America
The North America Uncomplicated Urinary Tract Infection (UTI) Treatment Market is a significant market segment in the global UTI treatment market. North America is expected to dominate the global UTI treatment market due to several factors, including the high prevalence of UTIs, high healthcare expenditure, and increasing awareness of UTI management.
In the United States, UTIs are one of the most common bacterial infections, with an estimated 8.1 Billion cases reported each year. This high prevalence of UTIs drives demand for UTI treatment products and services in the North American market.
The North American UTI treatment market is also characterized by the presence of key market players, such as F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, and Pfizer Inc., among others. These companies are involved in the development and commercialization of UTI treatment products, and they are expected to continue to drive growth in the North American UTI treatment market.
Moreover, initiatives and awareness programs undertaken by government organizations and non-governmental organizations in North America are expected to further boost the market growth. These initiatives focus on raising awareness about the importance of proper UTI management and improving access to UTI treatment products and services. Thus, North America is expected to possess 48% market share for uncomplicated UTIs treatment market in 2023.
Demand for alternative therapies creating lucrative opportunities for uncomplicated UTIs in Europe
The Europe Uncomplicated Urinary Tract Infection (UTI) Treatment Market is another significant market segment in the global UTI treatment market. Europe is expected to be a major contributor to the global UTI treatment market due to several factors, including the high incidence of UTIs, a growing geriatric population, and increasing demand for alternative therapies.
In Europe, UTIs are one of the most common bacterial infections, affecting Billions of people each year. The high incidence of UTIs drives demand for UTI treatment products and services in the European market. The Europe UTI treatment market is also characterized by the presence of key market players, such as Bayer AG, GlaxoSmithKline plc, and Pfizer Inc., among others. These companies are involved in the development and commercialization of UTI treatment products, and they are expected to continue to drive growth in the European UTI treatment market.
Furthermore, the increasing demand for alternative therapies is expected to further boost the market growth in Europe. Patients are increasingly seeking alternative therapies, such as herbal remedies and probiotics, for UTI treatment, which is driving demand for these products in the European market.
Additionally, government initiatives and awareness programs aimed at improving access to UTI treatment products and services are expected to further boost the market growth in Europe. Thus, Europe is expected to hold 40% market share for uncomplicated UTIs treatment market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Demand for over-the-counter medicines bolstering growth of retail pharmacies for uncomplicated UTI treatment
Retail pharmacies can be a good option for obtaining Uncomplicated Urinary Tract Infection (UTI) treatment medications for patients who do not require hospitalization or intensive monitoring. Retail pharmacies are widely available and convenient for patients to access.
Patients can consult with a pharmacist at a retail pharmacy to receive advice and recommendations on UTI treatment options. In addition, retail pharmacies may offer over-the-counter (OTC) UTI treatment options such as cranberry supplements or pain relief medications. Thus, retail pharmacies are expected to possess 47% market share for uncomplicated UTIs market in 2023.
Key players in the uncomplicated urinary tract infection treatment market are GlaxoSmithKline, Iterum Therapeutics, Inmunotek, Janssen Pharmaceuticals, Fimbrion Therapeutics, Pfizer, Allergan Plc, Bristol-Myers Squibb, Merck & Co., Inc., Cipla Inc.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 6.55 Billion |
| Market Value in 2033 | US$ 17 Billion |
| Growth Rate | CAGR of 10% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The uncomplicated urinary tract infection treatment market valuation is US$ 6.55 billion in 2023.
The market is likely to surge at a 10% CAGR, reaching US$ 17 billion by 2033.
Rising rates of UTI incidence is prominently fueling the adoption of uncomplicated urinary tract infection treatment.
Key challenge faced by market players include increasing antibiotic resistance.
North America exhibits significant profitability potential for the treatment due to advanced healthcare infrastructure.
1. Executive Summary | Uncomplicated Urinary Tract Infection Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Gepotidacin
5.3.2. Probenecid
5.3.3. Sulfonamide
5.3.4. Tetracycline
5.3.5. Nitrofuran
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
6.3.1. Hospital Pharmacies
6.3.2. Gynaecology and Urology Clinics
6.3.3. Retail Pharmacies
6.3.4. Online Drug Stores
6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. South Asia
7.3.5. East Asia
7.3.6. Oceania
7.3.7. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. The USA
8.2.1.2. Canada
8.2.2. By Drug Class
8.2.3. By Distribution Channel
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Drug Class
8.3.3. By Distribution Channel
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Drug Class
9.2.3. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Distribution Channel
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Drug Class
10.2.3. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Distribution Channel
10.4. Key Takeaways
11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. India
11.2.1.2. Malaysia
11.2.1.3. Singapore
11.2.1.4. Thailand
11.2.1.5. Rest of South Asia
11.2.2. By Drug Class
11.2.3. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Distribution Channel
11.4. Key Takeaways
12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Drug Class
12.2.3. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Distribution Channel
12.4. Key Takeaways
13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. Australia
13.2.1.2. New Zealand
13.2.2. By Drug Class
13.2.3. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Distribution Channel
13.4. Key Takeaways
14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Drug Class
14.2.3. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Distribution Channel
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Drug Class
15.1.2.2. By Distribution Channel
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Drug Class
15.2.2.2. By Distribution Channel
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Drug Class
15.3.2.2. By Distribution Channel
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Drug Class
15.4.2.2. By Distribution Channel
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Drug Class
15.5.2.2. By Distribution Channel
15.6. United Kingdom
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Drug Class
15.6.2.2. By Distribution Channel
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Drug Class
15.7.2.2. By Distribution Channel
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Drug Class
15.8.2.2. By Distribution Channel
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Drug Class
15.9.2.2. By Distribution Channel
15.10. India
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Drug Class
15.10.2.2. By Distribution Channel
15.11. Malaysia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Drug Class
15.11.2.2. By Distribution Channel
15.12. Singapore
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Drug Class
15.12.2.2. By Distribution Channel
15.13. Thailand
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Drug Class
15.13.2.2. By Distribution Channel
15.14. China
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Drug Class
15.14.2.2. By Distribution Channel
15.15. Japan
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Drug Class
15.15.2.2. By Distribution Channel
15.16. South Korea
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Drug Class
15.16.2.2. By Distribution Channel
15.17. Australia
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Drug Class
15.17.2.2. By Distribution Channel
15.18. New Zealand
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Drug Class
15.18.2.2. By Distribution Channel
15.19. GCC Countries
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Drug Class
15.19.2.2. By Distribution Channel
15.20. South Africa
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Drug Class
15.20.2.2. By Distribution Channel
15.21. Israel
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Drug Class
15.21.2.2. By Distribution Channel
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Drug Class
16.3.3. By Distribution Channel
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. GlaxoSmithKline
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Iterum Therapeutics
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Inmunotek
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Janssen Pharmaceuticals
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Fimbrion Therapeutics
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Pfizer
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Allergan Plc
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Bristol-Myers Squibb
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Merck & Co., Inc.
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Cipla Inc.
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Healthcare
November 2022
REP-GB-1451
250 pages
Explore Healthcare Insights
View Reports
Uncomplicated Urinary Tract Infection Treatment Market
